Abou Faddan Amr Hassan, Gaber Hisham Diab, Oamonov Daniar
Department of Urology, Faculty of Medicine, Assiut University, Assiut, Egypt.
Department of Dermatology and Andrology, Faculty of Medicine, Assiut University, Assiut, Egypt.
Arab J Urol. 2022 Feb 26;20(2):100-104. doi: 10.1080/2090598X.2021.2007464. eCollection 2022.
To investigate the effectiveness and safety of a tadalafil 5-mg single daily dose in the treatment of lifelong premature ejaculation (PE).
A total of 55 men with lifelong PE were enrolled in this study. The intravaginal ejaculatory latency time (IELT) and Premature Ejaculation Diagnostic Tool (PEDT) were used to assess the efficacy of tadalafil. Baseline recording of the IELT (using a stopwatch) and PEDT was done. Patients were randomised to take a single daily dose of tadalafil 5 mg or placebo. Re-assessment was done by IELT and PEDT after 1 and 3 months.
As regard, age, number of children, frequency of intercourse and duration of PE there are no statically significant differences between both groups. In both the tadalafil 5-mg and placebo groups the IELT statically significantly increased after 1 month by a mean (SD) of 4.8 (4.7) and 5 (4.9) s, and after 3 months by a mean (SD) of 6.6 (7) and 4.5 (9) s; and the PEDT scores significantly improved after 1 month by a mean (SD) of 2.1 (1.9) and 2 (1.5), and after 3 months by a mean (SD) of 3.5 (2.5) and 3.3 (2.2). However, there is was no statically significant difference between the tadalafil 5-mg and placebo groups for the IELT and PEDT at baseline or after 1 and 3 months of treatment.
Despite 5-mg tadalafil once daily being safe and it showed only a slight improvement in IELT and PEDT in the treatment of lifelong PE, failing to show any statistically significant difference from the placebo drug.: ED: erectile dysfunction; 5-HT: 5-hydroxytryptamine (serotonin); IELT: the intravaginal ejaculation latency time; ISSM: International Society of Sexual Medicine; PE: premature ejaculation; PEDT: Premature Ejaculation Diagnostic Tool; PDE5i: phosphodiesterase-5 inhibitor; SSRI: selective serotonin reuptake inhibitor.
探讨每日单次服用5毫克他达拉非治疗终生性早泄（PE）的有效性和安全性。
本研究共纳入55名终生性早泄男性。采用阴道内射精潜伏期（IELT）和早泄诊断工具（PEDT）评估他达拉非的疗效。使用秒表对IELT进行基线记录，并完成PEDT评估。患者被随机分为每日单次服用5毫克他达拉非或安慰剂组。在1个月和3个月后通过IELT和PEDT进行重新评估。
在年龄、子女数量、性交频率和早泄持续时间方面，两组之间无统计学显著差异。在5毫克他达拉非组和安慰剂组中，IELT在1个月后平均（标准差）分别显著增加4.8（4.7）秒和5（4.9）秒，在3个月后分别为6.6（7）秒和4.5（9）秒；PEDT评分在1个月后平均（标准差）分别显著改善2.1（1.9）和2（1.5），在3个月后分别为3.5（2.5）和3.3（2.2）。然而，在基线时以及治疗1个月和3个月后，5毫克他达拉非组和安慰剂组在IELT和PEDT方面无统计学显著差异。
尽管每日一次服用5毫克他达拉非是安全的，且在治疗终生性早泄时IELT和PEDT仅略有改善，但与安慰剂药物相比未显示出任何统计学显著差异。：ED：勃起功能障碍；5-HT：5-羟色胺（血清素）；IELT：阴道内射精潜伏期；ISSM：国际性医学学会；PE：早泄；PEDT：早泄诊断工具；PDE5i：磷酸二酯酶5抑制剂；SSRI：选择性5-羟色胺再摄取抑制剂。
